J
Janet E. Pope
Researcher at University of Western Ontario
Publications - 593
Citations - 30332
Janet E. Pope is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Rheumatoid arthritis & Population. The author has an hindex of 72, co-authored 557 publications receiving 25112 citations. Previous affiliations of Janet E. Pope include McGill University Health Centre & Jewish General Hospital.
Papers
More filters
Journal ArticleDOI
The Scleroderma Patient-centered Intervention Network (SPIN) Cohort : protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context
Linda Kwakkenbos,Lisa R. Jewett,Murray Baron,Susan J. Bartlett,Daniel E. Furst,Karen Gottesman,Dinesh Khanna,Vanessa L. Malcarne,Vanessa L. Malcarne,Maureen D. Mayes,Luc Mouthon,Serge Poiraudeau,Serge Poiraudeau,Maureen Sauve,Warren R. Nielson,Janet L. Poole,Shervin Assassi,Isabelle Boutron,Isabelle Boutron,Carolyn Ells,Cornelia H. M. van den Ende,Marie Hudson,Ann Impens,Annett Körner,Catarina Leite,Angela Costa Maia,Cindy Mendelson,Janet E. Pope,Russell Steele,Maria E. Suarez-Almazor,Sara Ahmed,Stephanie Coronado-Montoya,Vanessa C. Delisle,Shadi Gholizadeh,Yeona Jang,Brooke Levis,Katherine Milette,Sarah D. Mills,Ilya Razykov,Rina S. Fox,Brett D. Thombs,Brett D. Thombs +41 more
TL;DR: The use of the cohort multiple randomised controlled trial (cmRCT) design, the development of self-guided online interventions and partnerships with patient organisations will allow SPIN to develop, rigourously test and effectively disseminate psychosocial and rehabilitation interventions for people with SSc.
Journal ArticleDOI
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
Dinesh Khanna,Veronica J. Berrocal,Edward H. Giannini,James R. Seibold,Peter A. Merkel,Maureen D. Mayes,Murray Baron,Philip J. Clements,Virginia D. Steen,Shervin Assassi,Elena Schiopu,Kristine Phillips,Robert W. Simms,Yannick Allanore,Christopher P. Denton,Oliver Distler,Sindhu R. Johnson,Marco Matucci-Cerinic,Janet E. Pope,Susanna Proudman,Jeffrey Siegel,Weng Kee Wong,Athol U. Wells,Daniel E. Furst +23 more
TL;DR: The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs) in patients with early diffuse cutaneous systemic sclerosis.
Journal ArticleDOI
Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails—A Consensus of Systemic Sclerosis Experts
Kyle M. Walker,Janet E. Pope +1 more
TL;DR: In this paper, a survey of experts on systemic sclerosis management was conducted to gain consensus for SSc management, with a focus on the standardization of systemic sclerosis (SSc) management.
Journal ArticleDOI
A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases
Jason J. Lee,Janet E. Pope +1 more
TL;DR: The inflammatory rheumatologic diseases studied were all associated with high rates of VTEs—more than three times higher than in the general population.
Journal Article
Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
Boulos Haraoui,Edward C. Keystone,J. Carter Thorne,Janet E. Pope,Isaac Chen,Charles G Asare,Jonathan A Leff +6 more
TL;DR: Etanercept, a soluble tumor necrosis factor (TNF) receptor, provided a well tolerated and effective treatment option for some patients even when infliximab, a monoclonal antibody to TNF, had been ineffective.